Form: Tablets
Dosage: 20mg
Packaging: 14 gastro-resistant tablets

Active substance: rabeprazole

Form: gastro-resistant tablet

Dosage: Each Rabezol tablet contains 20 mg of rabeprazole

Packaging: Box of 14 tablets

Target: adults

Rabezol tablets are indicated for the treatment of

– duodenal or gastric ulcer

– GERD (erosive or ulcerative esophagitis symptomatic of gastroesophageal reflux disease)

– maintenance treatment of GERD

– Zollinger Ellison syndrome,

– eradication of Helicobacter pylori in gastro-duodenal ulcer disease, in combination with appropriate antibiotic therapy.

The normal dosage for the treatment of ulcers and GERD is 1 Rabezol tablet taken daily (in the morning or in the evening in the case of night-time reflux)

The duration of treatment depends on the symptoms and the evolution of the pathology.

In the treatment of Helicobacter pylori ulcers, Rabezol must be taken together with an appropriate antibiotic therapy (example of eradication treatment: The following combination of drugs is recommended for 7 days. Rabezol 20 mg twice daily + clarithromycin 500 mg twice daily and amoxicillin 1 g twice daily).

Prescription drugs. Please contact your doctor.

Notice of Trademark Infringement

Dear valued partners, customers and Dafra representatives,

It has come to our attention that unauthorized use of our company’s name and logo has been observed in various contexts in the African country Togo (https://www.dafrapharma-vet.com/). In order to avoid misunderstandings, ever misleading, we feel it is imperative to address this issue promptly and transparently.

Trademark infringement poses a significant threat not only to our brand integrity but also to the trust and credibility we have worked diligently to establish within our community. Our name and logo represent our values, quality, and commitment to excellence, and any unauthorized use undermines these principles.

We take trademark infringement seriously and are actively taking measures to address any instances of unauthorized use. This includes legal action against parties found to be infringing upon our intellectual property rights.

We urge our customers, partners, African representatives and the general public to remain vigilant and report any suspected instances of trademark infringement directly to us. Your cooperation in this matter is crucial in helping us protect our brand and preserve the integrity of our business.

As always, we remain dedicated to providing high quality medical solutions in the sub-Sahara region of Africa and maintaining the highest standards of integrity and professionalism.

Thank you for your continued support and trust in our company.

Dafra Pharma